Consolidated Financial Results
for the Three Months Ended June 30, 2026 [IFRS]

(Abridged)

August 6, 2026

Listed company:	M3, Inc.	Listing: Tokyo Stock Exchange
Securities code:	2413	URL: https://corporate.m3.com/en/
Representative:	Itaru Tanimura, Representative Director	
Contact:	Hirofumi Oba, Corporate Officer	Tel: +81-3-6229-8900
Scheduled date to commence dividend payments:		-

Preparation of supplementary materials on financial results: Yes
Holding of financial results briefing: Yes (for analysts and institutional investors)

(Amounts are rounded to the nearest million yen.)

1. Consolidated Financial Results for the Three Months Ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated Operating Results (Cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of the parent	
Three Months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	90,105	4.5	18,077	(8.6)	18,641	(5.3)	10,579	(21.8)	9,074	(23.4)
June 30, 2025	86,200	34.2	19,777	17.0	19,683	4.8	13,536	6.2	11,840	5.3

	Total comprehensive income		Basic earnings per share	Diluted earnings per share
Three Months ended	Millions of yen	%	Yen	Yen
June 30, 2026	14,075	13.5	13.60	13.59
June 30, 2025	12,403	(46.2)	17.44	17.43

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets	Equity per share attributable to owners of the parent
As of	Millions of yen	Millions of yen	Millions of yen	%	Yen
June 30, 2026	634,803	443,629	406,122	64.0	605.97
March 31, 2026	637,396	446,648	408,217	64.0	608.98

2. Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year ended March 31, 2026	–	0.00	–	22.00	22.00
Fiscal Year ending March 31, 2027 (Actual)	–				
Fiscal Year ending March 31, 2027 (Forecast)		0.00	–	–	–

Note:
1. Amendments to forecasts of dividends recently announced: None
2. Dividend forecast for the fiscal year ending March 31, 2027 is currently undetermined. It is to be determined after consideration of capital needs and condition of cash flow hereafter.

3. Consolidated Financial Results Forecasts for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes compared to the same period of the previous fiscal year.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six Months ending September 30, 2026	192,000	12.4	37,000	2.8	37,500	2.2	26,000	2.7	24,000	5.7	35.45
Fiscal Year ending March 31, 2027	400,000	13.8	80,000	8.8	81,000	6.2	56,000	3.6	53,000	7.9	78.29

Note: Amendments to forecasts of financial results recently announced: None

Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and accounting estimates
- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies other than item (i) above: None
- (iii) Changes in accounting estimates: None

(3) Number of shares issued (ordinary shares)

(i) Total number of shares issued at the end of the period (including treasury shares)	
As of June 30, 2026	679,124,800 shares
As of March 31, 2026	679,120,300 shares
(ii) Number of treasury shares at the end of the period	
As of June 30, 2026	11,695,139 shares
As of March 31, 2026	11,695,137 shares
(iii) Average number of shares outstanding during the period	
Three Months ended June 30, 2026	667,428,932 shares
Three Months ended June 30, 2025	678,863,207 shares

• Review of this financial report by certified public accountants or an audit firm: None

• Proper use of financial results forecasts and other special matters

(1) Disclaimer about forward-looking statements
The forward-looking statements herein are based on information available to the Company and on certain assumptions deemed to be reasonable at the date of publication of this document. They are not intended as the Company's commitment to achieve such forecasts, and actual results may differ significantly due to various factors.

(2) Supplementary materials on financial results
Supplementary materials on financial results will be posted on our website on Thursday, August 6, 2026.

1. Overview of Financial Results, etc.

(1) Overview of Financial Results for the Three Months Ended June 30, 2026

In Japan, we provide various services designed for healthcare professionals, centered on our website at m3.com with a membership of more than 350,000 physicians.

In Medical Platform segment, we offer a wide menu of services on the platform at m3.com, catering to various agendas and purposes of our clients. The services include MR-kun family services, which allow its registered physicians to proactively receive continuous and frequent information, marketing research services leveraging our panel of member healthcare professionals, and marketing support services for pharmaceutical companies to resolve fundamental drug-related challenges by utilizing the synergy of the M3 Group’s diverse data assets and technologies including AI. In addition, our group companies provide a variety of services for medical institutions, including AI-enabled electronic medical records (EMR), consultation support system, and a platform that allows for access to various medical AI centered on diagnostic imaging support, as well as external business succession support services for private practitioners using the panel of member physicians of m3.com. We also provide employee benefits services through EWEL,Inc., our new subsidiary acquired in April 2025, as part of the White Jack Project, aimed at maintaining people’s health from the pre-onset stage.

In Evidence Solution segment, our group companies operate businesses serving as the following organizations: CRO that supports clinical development operations and large-scale clinical research; SMO that supports the management and operations of overall activities at clinical trial sites; and PRO that provides support for recruiting participants and carrying out peripheral operations necessary to conduct clinical development and clinical research.

In Career Solution segment, M3 Career, Inc. primarily provides job search and placement support services to physicians and pharmacists.

Site Solution segment provides services that assist medical institutions with their operations.

Patient Solution segment provides patient support services targeting hospitalized patients, nursing facility users, and so forth through offerings including “CS (Care Support) Set.”

It also provides consumer-facing services, such as AskDoctors at <https://www.AskDoctors.jp/> (available in Japanese only). On this website, the member physicians of m3.com will answer questions from public users about health and diseases. Furthermore, M3 Education, Inc. provides medical and welfare professional education such as preparatory services for national examinations.

The M3 Group operates websites for healthcare professionals and has panels of physicians around the world, including Japan, the U.S., Europe, China, and South Korea, and the total number of healthcare professionals who have signed up for the websites and/or participated in the panels is now more than 7 million. Overseas segment provides global marketing research services using the panels of physicians, and it also offers services for pharmaceutical companies, career-related services focused on physicians, and others, primarily in the U.S. and Europe. Additionally, our offerings include clinical trial support services in North America, pharmaceutical database services in France, Germany, and Spain through the VIDAL Group, and the provision of SaaS-based EMR system “Weda” and other software for clinics primarily in France. We steadily expand business in other regions with a focus on Asia, especially India and South Korea, as well.

Consolidated financial results for the three months ended June 30, 2026 are as below.

(Millions of yen, unless otherwise stated)

	Three Months ended June 30, 2025 (April 1, 2025 to June 30, 2025)	Three Months ended June 30, 2026 (April 1, 2026 to June 30, 2026)	Year-on-year change		(Reference) Fiscal Year ended March 31, 2026 (April 1, 2025 to March 31, 2026)
Revenue	86,200	90,105	+3,905	+4.5%	351,363
Operating profit	19,777	18,077	(1,700)	(8.6%)	73,547
Profit before tax	19,683	18,641	(1,042)	(5.3%)	76,276
Profit	13,536	10,579	(2,957)	(21.8%)	54,046

Consolidated financial results by segment

(Millions of yen, unless otherwise stated)

		Three Months ended June 30, 2025 (April 1, 2025 to June 30, 2025)	Three Months ended June 30, 2026 (April 1, 2026 to June 30, 2026)	Year-on-year change	
Medical Platform	Segment revenue	25,274	25,585	+311	+1.2%
	Segment profit (loss)	8,981	8,872	(109)	(1.2%)
Evidence Solution	Segment revenue	6,219	5,691	(528)	(8.5%)
	Segment profit (loss)	1,314	879	(435)	(33.1%)
Career Solution	Segment revenue	8,280	7,999	(281)	(3.4%)
	Segment profit (loss)	3,665	3,597	(68)	(1.8%)
Site Solution	Segment revenue	12,996	14,159	+1,163	+9.0%
	Segment profit (loss)	727	15	(712)	(97.9%)
Patient Solution	Segment revenue	13,422	14,752	+1,330	+9.9%
	Segment profit (loss)	451	750	+299	+66.2%
Overseas	Segment revenue	20,725	22,748	+2,023	+9.8%
	Segment profit (loss)	4,852	4,615	(237)	(4.9%)
Other Emerging Businesses	Segment revenue	493	480	(12)	(2.5%)
	Segment profit (loss)	252	133	(119)	(47.3%)
Adjustment	Segment revenue	(1,208)	(1,308)	―	―
	Segment profit (loss)	(466)	(784)	―	―
Total	Revenue	86,200	90,105	+3,905	+4.5%
	Operating profit (loss)	19,777	18,077	(1,700)	(8.6%)

1) Medical Platform

Segment revenue amounted to 25,585 million yen, up 1.2% year on year, with segment profit of 8,872 million yen, down 1.2% year on year. This is attributable to a decline in revenue from the pharmaceutical marketing support business, a high-margin area, while businesses such as digitalization support for medical practices showed solid performance.

2) Evidence Solution

Segment revenue amounted to 5,691 million yen, down 8.5% year on year, with segment profit of 879 million yen, down 33.1% year on year. This is attributable to the absence of the contribution from relatively high-margin projects and large-scale projects recorded in the same period of the previous fiscal year.

3) Career Solution

Segment revenue amounted to 7,999 million yen, down 3.4% year on year, with segment profit of 3,597 million yen, down 1.8% year on year. This is mainly attributable to a decline in revenue from job search and placement support services for physicians and pharmacists.

4) Site Solution

Segment revenue amounted to 14,159 million yen, up 9.0% year on year. This is attributable to the steady growth across businesses, particularly in the medical institution business and the hospice business. Segment profit amounted to 15 million yen, down 97.9% year on year. This is mainly attributable to an increase in upfront investments for new facility openings in the U.S. business and in-home nursing business.

5) Patient Solution

Segment revenue amounted to 14,752 million yen, up 9.9% year on year, with segment profit of 750 million yen, up 66.2% year on year. This is mainly attributable to the growing user base driven by new contracts for CS Set and the change in accounting treatment for original patient gowns from the fourth quarter of the previous fiscal year.

6) Overseas

Segment revenue amounted to 22,748 million yen, up 9.8% year on year. This is attributable to the revenue growth across regions driven by positive foreign exchange impact from the year-on-year trend of yen depreciation. Segment profit amounted to 4,615 million yen, down 4.9% year on year, mainly due to the impact of proactive upfront investments.

7) Other Emerging Businesses

Segment revenue amounted to 480 million yen, down 2.5% year on year, with segment profit of 133 million yen, down 47.3% year on year.

Combining all of the above, revenue of the M3 Group for the three months ended June 30, 2026 amounted to 90,105 million yen, up 4.5% year on year, with operating profit of 18,077 million yen, down 8.6% year on year, profit before tax of 18,641 million yen, down 5.3% year on year, and profit of 10,579 million yen, down 21.8% year on year.